ESMO 2024 - Israel (Izzy) Lowy
ESMO 2024, which followed hot on the heels of this year’s World Conference on Lung Cancer, was abuzz with data around PD-1 inhibitors, LAG-3 inhibitors, and the possibilities for using existing therapies as combination treatment to address additional cancers.
Onsite in Barcelona, web editor Nicole Raleigh sat down with Israel (Izzy) Lowy, senior VP of clinical oncology at Regeneron, to discuss the company’s five-year survival data presented on Libtayo (PD-1 inhibitor) as a first-line monotherapy in advanced non-small cell lung cancer (NSCLC), as well as Regeneron’s general commitment to transforming care for people living with other difficult-to-treat cancers, including advanced melanoma and advanced non-melanoma skin cancer. And then, what the future might hold.
Take a watch of the video below, and don’t forget to catch up with other reporting from ESMO 2024 at the sprawling Fira Gran Via centre in Barcelona, including a discussion with Illumina’s Sven Schaffer on how a simple blood draw can transform clinical practice in oncology, and a congress overview with experts from EVERSANA.
